Product
Rucaparib + Nivolumab
1 clinical trial
1 indication
Indication
Small Cell Lung CancerClinical trial
Phase II Study of Combination Rucaparib With Nivolumab in Platinum-Sensitive Small Cell Lung Carcinoma Patients as Maintenance After Induction Therapy With Platinum DoubletStatus: Active (not recruiting), Estimated PCD: 2022-11-15